o	EXACT has reported positive early efficacy and safety interim data from its
Phase 1 ACTIVATE trial in in cancer patients with liver metastases of colorectal
origin.

o	Valuable guidance has been received from the FDA in a Pre-IND meeting for the
Phase 2 ENACT trial in pancreatic cancer.

o	With FDA's guidance, the Company will now focus on the ENACT trial and stop
recruitment into the ACTIVATE trial.

o	The planned follow-up of the recruited patients will continue.  So far, there
has been no change to the previously reported excellent safety profile of PS101.


Oslo, Norway, August 6, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a
clinical stage precision medicine company utilizing the power of ultrasound to
enable targeted drug delivery in oncology, announces that it will now be
focusing all clinical efforts on the upcoming Phase 2 ENACT trial in locally
advanced pancreatic cancer and is stopping recruitment in the Phase 1 ACTIVATE
clinical trial in cancer patients with liver metastases of colorectal origin.

Previously, the Phase 1 ACTIVATE trial reported positive interim efficacy and
safety data. The enrolled patients will be followed through the planned
follow-up. The final results from the ACTIVATE Phase 1 trial (11 patients) will
be reported after completion of independent blinded review, expected early 2025.
So far, there has been no change to the previously reported excellent safety
profile of PS101 in the ACTIVATE trial.

Dr Per Walday, CEO of EXACT Therapeutics commented: "EXACT will now focus its
full resources on the ENACT Phase 2 trial in locally advanced pancreatic cancer